Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

Table 2 Virological, serological and biochemical response after 12 mo of tenofovir disoproxil fumarate therapy n (%)

	All (n = 174)	Compensated LC (n = 117)	Decompensated LC (n = 57)	P value
Virological response
Change in serum HBV DNA level
Month 6	-4.07 ± 1.39	-4.00 ± 1.42	-4.20 ± 1.32	0.581
Month 12	-4.30 ± 1.38	-4.20 ± 1.39	-4.49 ± 1.35	0.310
Serum HBV DNA undetectable1
Month 6	96 (55.2)	67 (57.3)	29 (50.9)	0.516
Month 12	144 (82.8)	104 (88.9)	40 (70.2)	0.005
Serological
HBeAg seroconversion
Month 6	6/78 (7.7)	3/50 (6.0)	3/28 (10.7)	0.664
Month 12	7/78 (8.9)	3/50 (6.0)	4/28 (14.2)	0.373
HBeAg loss
Month 6	2/78 (2.5)	2 (4.0)	0 (0)	0.427
Month 12	2/78 (2.5)	2 (4.0)	0 (0)	0.517
Biochemical
ALT normalization
Month 6	108 (62.0)	72 (61.5)	36 (63.2)	0.869
Month 12	121 (69.5)	77 (65.8)	44 (77.2)	0.161

¹HBV DNA < 116 copies/mL. LC: Liver cirrhosis. HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen.